Efficacy, safety, and tolerability of switching to long-acting cabotegravir plus rilpivirine versus continuing fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with HIV, 12-month results (SOLAR): a randomised, open-label, phase 3b, non-inferiority trial

Publication | Closed Access

DOI

Citations

References

2023

Year

Moti Ramgopal, Antonella Castagna, Charles Cazanave, Vicens Díaz-Brito, Robin Dretler, Shinichi Oka, Olayemi Osiyemi, Sharon Walmsley, James J. Sims, Giovanni Di Perri,

The Lancet HIV

Phase 3BHealth SciencesTreatment And PreventionMedicineAntiviral Drug DevelopmentClinical TrialsAntiviral TherapyPharmacotherapyNon-inferiority TrialTenofovir AlafenamideHivAntiviral DrugPharmacologyDrug Resistance